Daily Sepsis Research Analysis
Three papers stand out today: a Nature Communications mechanistic study reveals gut-primed neutrophils activate Kupffer cells via NETs to drive sepsis-associated liver injury; an ACS Nano translational study presents CTI-111, a human macrophage membrane-coated nanoparticle that sequesters toxins and cytokines and improves survival in murine sepsis; and a JAMIA paper proposes a standardized Effectiveness–Efficiency–Utility framework to evaluate and deploy sepsis prediction AI across 977,506 admis
Summary
Three papers stand out today: a Nature Communications mechanistic study reveals gut-primed neutrophils activate Kupffer cells via NETs to drive sepsis-associated liver injury; an ACS Nano translational study presents CTI-111, a human macrophage membrane-coated nanoparticle that sequesters toxins and cytokines and improves survival in murine sepsis; and a JAMIA paper proposes a standardized Effectiveness–Efficiency–Utility framework to evaluate and deploy sepsis prediction AI across 977,506 admissions.
Research Themes
- Innate immune mechanisms and organ injury in sepsis (gut–liver axis, NETs, Kupffer cell activation)
- Nanotechnology-based decoy therapies that neutralize inflammatory mediators in sepsis
- Pragmatic evaluation frameworks for deploying sepsis prediction AI (balancing accuracy, alert burden, and lead time)
Selected Articles
1. Gut-primed neutrophils activate Kupffer cells to promote hepatic injury in mouse sepsis.
This mechanistic study supports that gut-primed neutrophils exacerbate sepsis-associated liver injury by releasing NETs that activate Kupffer cells, with increased iNOS expression in wild-type septic mice and reduction when NETosis (PAD4-dependent) is impaired. The findings define a gut–liver immune axis that drives hepatic injury in sepsis.
Impact: It provides a previously underappreciated mechanism linking the gut–liver axis, neutrophil NETs, and Kupffer cell activation in sepsis-related organ injury, opening therapeutic avenues targeting NETosis or Kupffer cell signaling.
Clinical Implications: Although preclinical, the data suggest that PAD4/NETosis inhibition or modulation of Kupffer cell activation could mitigate sepsis-associated liver injury. Strategies that limit gut-primed neutrophil trafficking or NET release may prevent hepatic complications.
Key Findings
- Gut-primed neutrophils migrate via the portal vein and release NETs that activate Kupffer cells.
- Kupffer cell iNOS expression increases in wild-type septic mice but is reduced when PAD4-dependent NETosis is impaired.
- Findings delineate a gut–liver immune axis contributing to hepatic injury during sepsis.
Methodological Strengths
- Use of genetic perturbation of NETosis (PAD4-related) to probe causality in Kupffer cell activation.
- Mechanistic focus on gut–liver crosstalk with cellular players (neutrophils, Kupffer cells) in vivo.
Limitations
- Preclinical murine model limits direct clinical generalizability.
- Abstracted data emphasize iNOS expression; functional and translational endpoints (e.g., liver function, survival) are not detailed in the provided text.
Future Directions: Test pharmacologic PAD4/NETosis inhibitors and Kupffer cell signaling modulators in sepsis models; map trafficking signals for gut-primed neutrophils; validate biomarkers of NET-driven hepatic injury in patients.
Sepsis-induced liver injury is common, but the underlying mechanisms remain poorly understood. Given the critical role of gut-liver crosstalk in sepsis, we hypothesize that gut-trained neutrophils, migrating via the portal vein, release neutrophil extracellular traps (NETs) to activate Kupffer cells, thereby exacerbating hepatic injury during sepsis. Here we show that iNOS expression in Kupffer cells increases in septic wild type mice but decreases in PAD4
2. Natural Macrophage Membrane-Coated Nanoparticles as a Multifaceted Sepsis Therapeutic to Sequester Inflammatory and Toxic Mediators.
CTI-111, a human macrophage membrane-coated nanoparticle, sequesters microbial toxins and pro-inflammatory cytokines, dampening inflammation and improving survival across multiple murine sepsis models. Ex vivo, CTI-111 binds multiple human sepsis-associated cytokines in septic serum, supporting translational potential.
Impact: Introduces a decoy nanoparticle therapeutic concept with demonstrated survival benefit and broad mediator sequestration, addressing a longstanding gap in immunoregulatory therapy for sepsis.
Clinical Implications: If safety and pharmacokinetics are favorable, CTI-111 could serve as an adjunctive therapy to antibiotics by neutralizing circulating toxins and cytokines, potentially reducing organ injury and mortality.
Key Findings
- CTI-111 sequesters soluble microbial toxins and pro-inflammatory cytokines from multiple sources.
- Therapeutic administration of CTI-111 reduces inflammation and improves survival in multiple murine sepsis models.
- Ex vivo, CTI-111 binds multiple human sepsis-associated cytokines in septic serum.
Methodological Strengths
- Demonstration across multiple murine sepsis models enhances robustness.
- Ex vivo validation in human septic serum supports translational relevance.
Limitations
- Preclinical data; human safety, immunogenicity, and pharmacokinetics are unknown.
- Manufacturing scalability and consistency of membrane-coating may pose translational challenges.
Future Directions: Conduct GLP toxicology, PK/PD studies, and first-in-human trials; compare with hemoadsorption; define optimal timing relative to infection source control and antibiotics.
Bacterial sepsis is a life-threatening immune dysregulation triggered by bacterial infection and propagated by a dysfunctional host response, culminating in systemic tissue damage and multiorgan failure. In the United States, sepsis results in the hospitalization of more than one million patients annually and accounts for nearly one in three hospital deaths. Despite decades of efforts to develop immunoregulatory sepsis therapies, no clinically approved treatments exist. Recent advances in nanotechnology have introduced innovative approaches, including cellular nanodecoys synthesized from natural macrophage membranes coated onto polymeric nanoparticle cores. Here we introduce a human macrophage membrane-derived drug candidate, CTI-111, capable of sequestering soluble microbial toxins, drivers of inflammation, and pro-inflammatory cytokines from multiple sources. Therapeutic administration of CTI-111 reduces inflammation and improves survival in multiple murine sepsis models. We further demonstrate that CTI-111 can bind multiple sepsis-associated human cytokines in the complex environment of septic serum ex vivo. Together, these findings highlight the potential of CTI-111 as a multifaceted therapy for sepsis.
3. A novel, standardised approach to balancing effectiveness, efficiency and utility of surveillance AI prediction models for hospitalised patients using sepsis prediction as an exemplar.
Using 977,506 admissions across 7 hospitals, the authors propose an EEU (Effectiveness–Efficiency–Utility) graphical framework that integrates accuracy, alert burden, and lead time to select optimal alert thresholds for sepsis prediction. The framework corrects biases from conventional metrics that ignore alert timing and mix sample- vs admission-level evaluations.
Impact: Provides an actionable, standardized evaluation for sepsis AI deployment that balances clinical benefits with workflow impacts, addressing a key barrier to safe and effective implementation.
Clinical Implications: Hospitals can adopt EEU plots to set sepsis alert thresholds that improve timeliness while minimizing alert fatigue, aligning model performance with clinical operations.
Key Findings
- Introduces an EEU framework integrating accuracy, alert burden, and alert lead time to evaluate sepsis prediction.
- Applied to 977,506 admissions from 7 public hospitals, yielding threshold choices that differ from AUROC-based selections.
- Highlights biases from conventional metrics that ignore alert timing and mix sample- and admission-level evaluations.
Methodological Strengths
- Very large multicenter dataset (977,506 admissions) enabling robust, admission-level evaluation across thresholds.
- Explicit incorporation of alert timing relative to clinical events, directly addressing utility.
Limitations
- Retrospective evaluation within a specific health system; generalizability to other institutions and models needs testing.
- Does not test patient-level outcomes after threshold changes; prospective implementation studies are required.
Future Directions: Prospectively validate EEU-guided thresholds on clinical outcomes, extend to other adverse-event models, and integrate cost and equity metrics.
OBJECTIVE: To introduce a novel, standardised approach to evaluating AI prediction models in balancing effectiveness, efficiency and utility, using a sepsis prediction model case study. MATERIALS AND METHODS: Retrospective patient data from electronic medical records of 7 public hospitals was used to retrain and evaluate a machine learning sepsis prediction model. Four conventional metrics-area under the receiver operating curve (AUROC), sensitivity, positive predictive value, and specificity-were compared with a novel graphical display integrating metrics of predictive accuracy (effectiveness), alert burden (efficiency) and lead time of alerts relative to clinical events (utility) for different alert thresholds. RESULTS: The dataset comprised 977,506 inpatient admissions. The novel methodology produced a plot of four vertically aligned graphs that enables decision-makers to identify an alert threshold that optimally balances effectiveness, efficiency and utility (EEU) at the level of an entire admission, and which differs from that derived using conventional metrics. DISCUSSION: Conventional evaluation metrics do not consider alert timing relative to clinical events and are often applied to different evaluation datasets (sample and admission level), introducing bias and confusion. In contrast, the EEU methodology (i) generates admission level evaluations at different alert thresholds; (ii) measures alert timing relative to clinical events; and (iii) provides a visual display that enables identification of the alert threshold that optimally balances EEU factors. CONCLUSION: Evaluations of prediction models for adverse events in hospitalised patients should incorporate the EEU approach in assessing model suitability and selecting alert thresholds.